
    
      Pembrolizumab has been approved by the U.S. Food and Drug Administration for the treatment of
      patients with unresectable metastatic melanoma and disease progression following ipilimumab
      and if BRAF V600 mutation positive, a BRAF inhibitor. The Expanded Access Program (EAP) for
      this medicine in the U.S. is closed. The EAP will continue outside the U.S.
    
  